source
- Boehringer Ingelheim strikes $7.4 billion deal with Sino Biopharma for preclinical ADC and TCE programsBoehringer Ingelheim announced a major licensing agreement with China's Sino Biopharmaceutical, paying $358 million upfront for a six‑program option covering preclinical antibody‑drug conjugates an…
- CVS Health to split into two publicly traded companies amid regulatory scrutiny of its pharmacy‑insurer integrationCVS Health announced it will separate into two independent, publicly traded companies. The move undoes years of acquisitions that combined a pharmacy chain, a pharmacy‑benefit manager and an insura…